Recent discovery and development of inhibitors targeting coronaviruses
- 30 January 2020
- journal article
- review article
- Published by Elsevier BV in Drug Discovery Today
- Vol. 25 (4), 668-688
- https://doi.org/10.1016/j.drudis.2020.01.015
Abstract
No abstract availableKeywords
Funding Information
- PSG Management
This publication has 154 references indexed in Scilit:
- Suppression of Coronavirus Replication by Cyclophilin InhibitorsViruses, 2013
- Inhibition of novel β coronavirus replication by a combination of interferon-α2b and ribavirinScientific Reports, 2013
- A Systematic Screen of FDA-Approved Drugs for Inhibitors of Biological Threat AgentsPLOS ONE, 2013
- Severe Acute Respiratory Syndrome Coronavirus Papain-like Novel Protease Inhibitors: Design, Synthesis, Protein−Ligand X-ray Structure and Biological EvaluationJournal of Medicinal Chemistry, 2010
- The IFITM Proteins Mediate Cellular Resistance to Influenza A H1N1 Virus, West Nile Virus, and Dengue VirusCell, 2009
- Structure-Based Design, Synthesis, and Biological Evaluation of a Series of Novel and Reversible Inhibitors for the Severe Acute Respiratory Syndrome−Coronavirus Papain-Like ProteaseJournal of Medicinal Chemistry, 2009
- A noncovalent class of papain-like protease/deubiquitinase inhibitors blocks SARS virus replicationProceedings of the National Academy of Sciences of the United States of America, 2008
- Design, synthesis and antiviral efficacy of a series of potent chloropyridyl ester-derived SARS-CoV 3CLpro inhibitorsBioorganic & Medicinal Chemistry Letters, 2008
- Structure-based design, synthesis, and biological evaluation of peptidomimetic SARS-CoV 3CLpro inhibitorsBioorganic & Medicinal Chemistry Letters, 2007
- The S proteins of human coronavirus NL63 and severe acute respiratory syndrome coronavirus bind overlapping regions of ACE2Virology, 2007